← Back to All Filings

BioNTech CEO Ugur Sahin Discloses ~15.6% Stake (~$3.5B Holding)

High SignificanceMarch 25, 2026 at 6:02:10 PM EDT

BioNTech SE

$BNTX3CIK: 0001776985

Subscribe to track BNTX

Premium users can add ticker alerts and receive realtime notification updates.

Filing Summary

BioNTech CEO Ugur Sahin Discloses 15.6% Stake ($3.5B Holding)

Company: BioNTech SE (BNTX) Form: 3 (Initial Statement) | Filed: 2026-03-25 Significance: High

Insider: Sahin Ugur Title: Chief Executive Officer | Relationship: Officer, 10% Owner

Holdings Disclosure: • Total Shares Held: 40,990,997 • Ownership Stake: ~15.56% of Shares Outstanding • Holding Value: ~$3.49 Billion (Est. based on Market Cap) • Structure: Majority held indirectly via Medine GmbH

Key Insight: CEO Ugur Sahin confirms massive 15.6% ownership stake in BioNTech. While a Form 3 is a statement of existing ownership rather than a new trade, the magnitude of the holding ($3.5B+) underscores significant alignment with shareholders.

Market Context: BioNTech has a market cap of $22.45B. This filing solidifies the CEO's position as a controlling stakeholder.

View Full Filing

Comprehensive Analysis

SEC Filing Analysis: BioNTech SE (BNTX)

Executive Summary

  • Trading Significance: High
  • Key Takeaway: CEO Ugur Sahin discloses a massive 15.6% ownership stake (~41M shares), confirming his status as a dominant controlling shareholder.
  • Market Impact: Neutral to Bullish (Long-term confidence signal, though no immediate open market purchase occurred).

Company Information

FieldValue
CompanyBioNTech SE
Ticker SymbolBNTX
CIK0001776985
IndustryBiological Products

Insider Information

FieldValue
NameSahin Ugur
CIK0002123975
Title/PositionChief Executive Officer
RelationshipOfficer, 10% Owner

Transaction Details (Form 3 - Initial Statement)

FieldValue
Form Type3
Report Date2026-03-18
Transaction CodeNone (Initial Ownership Disclosure)
Security TypeOrdinary Shares
Total Shares Held40,990,997
Estimated Holding Value~$3.49 Billion
Ownership TypeIndirect (Medine GmbH) & Direct

Financial Impact Assessment

Ownership Materiality

MetricValue
Total Holdings Value~$3.49 Billion
% of Market Cap~15.56%
Shares Held40,990,997
% of Shares Outstanding15.56%
Materiality AssessmentHighly Significant

Impact Evaluation

  • Market Cap Context: For a $22.45 billion company, a single insider holding ~15.6% of the equity is exceptionally high concentration.
  • Ownership Concentration: Ugur Sahin controls over 40 million shares. 40,132,788 shares are held indirectly through Medine GmbH, of which he is the sole shareholder.
  • Dilution Impact: The filing also discloses various options and PSUs totaling approximately 171,000 shares. Relative to the 263.4M shares outstanding, potential dilution from these specific derivatives is negligible (<0.07%).
  • Transaction Significance: While this is a Form 3 (reporting existing holdings) rather than a Form 4 (new transaction), the disclosure of a >10% stake is critical for market structure analysis.

Market Impact Analysis

Stock Impact Prediction

  • Direction: Neutral
  • Reasoning: This filing does not represent new buying pressure but rather transparency regarding the CEO's massive existing stake. It confirms strong alignment but doesn't change the float dynamics immediately.

Volume & Sentiment

  • Expected Volume Impact: Minimal immediate impact.
  • Sentiment Indicator: Bullish (Long-term). High insider ownership by a founder/CEO is generally correlated with long-term performance alignment.

Investment Insights

Positive Market Indicators

  • **High
Topics:#BNTX#BioNTech#UgurSahin#InsiderHoldings#Form3#BiotechStocks#MarketAnalysis#StockMarket#SECFiling#HighSignificance

Get Real-Time Alerts

Join our community to receive instant notifications when high-significance filings are published

Important Disclaimer

This content is drawn from public SEC filings and may contain errors. It is for informational purposes only and is not investment, legal, or tax advice.

Nothing here is a recommendation to buy, sell, or hold any security. Do your own due diligence.